Evidence map›Paper›PMID 20195466›Full record

ArticlePloS one2010

Cyr61/CCN1 displays high-affinity binding to the somatomedin B(1-44) domain of vitronectin.

Ivo M B Francischetti, Michalis Kotsyfakis, John F Andersen, Jan Lukszo

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. An overview of CCN4 (WISP1) role in human diseases.Journal of translational medicine · 2024
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Ivo M B FrancischettiSection of Vector Biology, Laboratory of Malaria and Vector Research, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America. ifrancischetti@niaid.nih.gov
Michalis Kotsyfakis
John F Andersen
Jan Lukszo
Institute of Parasitology · CZNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USVector (United States) · US

Funding

Vector-Borne Diseases: Biology Of Vector Host RelationshipZIAAI000810 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI RIBEIRO, JOSE · 2009 to 2025
$20.8M
Vector-Borne Diseases: Molecular Mechanisms in Vector-Host InteractionsZIAAI001012 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI RIBEIRO, JOSE · 2009 to 2025
$9.4M
Intramural NIH HHS
6 · The paper itself

Abstract

backgroundCyr61 is a member of the CCN (Cyr61, connective tissue growth, NOV) family of extracellular-associated (matricellular) proteins that present four distinct functional modules, namely insulin-like growth factor binding protein (IGFBP), von Willebrand factor type C (vWF), thrombospondin type 1 (TSP), and C-terminal growth factor cysteine knot (CT) domain. While heparin sulphate proteoglycans reportedly mediate the interaction of Cyr61 with the matrix and cell surface, the role of other extracellular associated proteins has not been revealed. METHODS AND

findingsIn this report, surface plasmon resonance (SPR) experiments and solid-phase binding assays demonstrate that recombinant Cyr61 interacts with immobilized monomeric or multimeric vitronectin (VTNC) with K(D) in the nanomolar range. Notably, the binding site for Cyr61 was identified as the somatomedin B domain (SMTB(1-44)) of VTNC, which mediates its interaction with PAI-1, uPAR, and integrin alphav beta3. Accordingly, PAI-1 outcompetes Cyr61 for binding to immobilized SMTB(1-44), and Cyr61 attenuates uPAR-mediated U937 adhesion to VTNC. In contrast, isothermal titration calorimetry shows that Cyr61 does not display high-affinity binding for SMTB(1-44) in solution. Nevertheless, competitive ELISA revealed that multimeric VTNC, heat-modified monomeric VTNC, or SMTB(1-44) at high concentrations attenuate Cyr61 binding to immobilized VTNC, while monomeric VTNC was ineffective. Therefore, immobilization of VTNC exposes cryptic epitopes that recognize Cyr61 with high affinity, as reported for a number of antibodies, beta-endorphin, and other molecules.

conclusionsThe finding that Cyr61 interacts with the SMTB(1-44) domain suggests that VTNC represent a point of anchorage for CCN family members to the matrix. Results are discussed in the context of the role of CCN and VTNC in matrix biology and angiogenesis.

Indexed as

Amino Acid SequenceBinding, CompetitiveBinding SitesCysteine-Rich Protein 61Enzyme-Linked Immunosorbent AssayHumansIntegrin alphaVbeta3Molecular Sequence DataPlasminogen Activator Inhibitor 1Protein BindingProtein MultimerizationSequence Homology, Amino AcidSomatomedinsSurface Plasmon ResonanceU937 CellsVitronectinCysteine-Rich Protein 61Integrin alphaVbeta3Plasminogen Activator Inhibitor 1somatomedin BSomatomedinsVitronectin

Identifiers

PMID20195466
PMCPMC2829074
OpenAlexW2050041926

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.